Literature DB >> 17878128

A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer.

Catherine E Jansen1, Christine A Miaskowski, Marilyn J Dodd, Glenna A Dowling.   

Abstract

PURPOSE/
OBJECTIVES: To identify which neuropsychological tests have been used to evaluate chemotherapy-induced impairment in various domains of cognitive function in patients with breast cancer and to determine the sensitivity of each of the tests through estimation of effect size. DATA SOURCES: Original studies published from 1966-June 2006. DATA SYNTHESIS: Although an array of neuropsychological tests are available to measure the various domains of cognitive function, information is lacking regarding the sensitivity and specificity of the tests to detect changes in cognitive function from chemotherapy.
CONCLUSIONS: This meta-analysis provides initial data on the sensitivity of some neuropsychological tests to determine chemotherapy-induced changes in cognitive function in patients with breast cancer. IMPLICATIONS FOR NURSING: The identification of sensitive neuro-psychological tests is crucial to further understanding of chemotherapy-induced cognitive impairments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878128     DOI: 10.1188/07.ONF.997-1005

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  20 in total

1.  Potential factors associated with perceived cognitive impairment in breast cancer survivors.

Authors:  Jamie S Myers; Jo A Wick; Jennifer Klemp
Journal:  Support Care Cancer       Date:  2015-04-03       Impact factor: 3.603

Review 2.  A framework for assessment in oncology rehabilitation.

Authors:  Laura S Gilchrist; Mary Lou Galantino; Meredith Wampler; Victoria G Marchese; G Stephen Morris; Kirsten K Ness
Journal:  Phys Ther       Date:  2009-01-15

Review 3.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

Review 4.  Clearing the air: a review of our current understanding of "chemo fog".

Authors:  Erin O'Farrell; Joyce MacKenzie; Barbara Collins
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

5.  Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.

Authors:  Lisa M Wu; Molly L Tanenbaum; Marcel P J M Dijkers; Ali Amidi; Simon J Hall; Frank J Penedo; Michael A Diefenbach
Journal:  Soc Sci Med       Date:  2016-03-17       Impact factor: 4.634

Review 6.  Assessing cognitive function in adults during or following chemotherapy: a scoping review.

Authors:  Karin Olson; Joanne Hewit; Linda G Slater; Thane Chambers; Deborah Hicks; Anna Farmer; Kathryn Grattan; Shawn Steggles; Bryan Kolb
Journal:  Support Care Cancer       Date:  2016-04-11       Impact factor: 3.603

7.  Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of Meta-Analyses.

Authors:  Todd S Horowitz; Melissa Treviño; Ingrid M Gooch; Korrina A Duffy
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

8.  Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.

Authors:  Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

Review 9.  Cognitive impairment after cytotoxic chemotherapy.

Authors:  Petra Huehnchen; Antonia van Kampen; Wolfgang Boehmerle; Matthias Endres
Journal:  Neurooncol Pract       Date:  2019-11-04

10.  Learning and memory performance in breast cancer survivors 2 to 6 years post-treatment: the role of encoding versus forgetting.

Authors:  James C Root; Charissa Andreotti; Loretta Tsu; Timothy M Ellmore; Tim A Ahles
Journal:  J Cancer Surviv       Date:  2015-12-12       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.